bimekizumab Archives -

The FDA has delivered a blow to UCB’s late-stage pipeline, after saying it is unable to approve its

FDA rejects UCB’s psoriasis therapy bimekizumab

https://pharmaphorum.com/news/fda-rejects-ucbs-psoriasis-therapy-bimekizumab/

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

https://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/

UCB’s bimekizumab hasn’t been approved for marketing in Europe yet, but has already been given the nod for

UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme

https://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug,

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial

https://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and

UCB posts more supportive data from Humira rival bimekizumab

https://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/

The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy

UCB’s bimekizumab tops J&J’s Stelara in psoriasis study

https://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/

bimekizumab